Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone

23rd March 2026 Uncategorised 0

Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the company closer to FDA submission.

More: Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
Source: News